REGNREGENERON PHARMACEUTICALS, INC.

• 2026-09-03 · McCourt Marion (EVP Commercial) · SELL
• 2026-09-03 · Guarini Kathryn (Director) · SELL
• 2026-09-03 · Guarini Kathryn (Director) · OTHER
• 2026-08-21 · LAROSA JOSEPH J (EVP General Counsel and Secret) · OTHER

• 2026-07-07 · Ro Khanna · BUY · $1,001 - $15,000
• 2026-05-15 · Gilbert Cisneros · SELL · $1,001 - $15,000
• 2026-03-27 · Alan Armstrong · BUY · $1,001 - $15,000
• 2025-04-10 · Hon. Byron Donalds · SELL · $1,001 - $15,000
• 2024-11-13 · Hon. Jonathan Jackson · SELL · $15,001 - $50,000

• Regeneron faces $0.18 per share earnings headwind from Sanofi deal
• Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
• Regeneron: The Easy Money Has Been Made (Rating Downgrade)
• An $8 Billion Reason Why Regeneron Stock Is in Focus
• Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript